ADMA Biologics Inc reports results for the quarter ended December 31 - Earnings Summary

• ADMA Biologics Inc ADMA.OQ reported quarterly adjusted earnings of 14 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -8 cents. The mean expectation of three analysts for the quarter was for earnings of 15 cents per share. Wall Street expected results to range from 14 cents to 16 cents per share.

• Revenue rose 59.1% to $117.55 million from a year ago; analysts expected $112.80 million.

• ADMA Biologics Inc's reported EPS for the quarter was 46 cents​.

• The company reported quarterly net income of $111.9 million.

• ADMA Biologics Inc shares had fallen by 4.4% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 3.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for ADMA Biologics Inc is $25.00

This summary was machine generated from LSEG data March 4 at 12:23 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)